Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Reirradiation for Recurrent HNSCC
NCT03317327Phase 2Completed
- Sponsor
- Oslo University Hospital
- Start
- Sep 2017
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Oslo University Hospital. Started Sep 2017; status: completed.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03317327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03317327.